UFP Technologies
Designs and manufactures custom single-use medical devices, sterile packaging, and engineered components.
Something off on this page? Send us feedback.
Profile
Develops and manufactures custom single-use and single-patient devices, sterile packaging, and engineered components through outsourced design and production programs. Medical markets drive most sales, while the two largest customers together account for nearly half of revenue.
Designs, develops, and manufactures custom single-use and single-patient devices through MedTech, alongside non-medical work in Advanced Components. Medical offerings span interventional and surgical devices, sterile packaging, infection-prevention and robotic-surgery drapes, orthopedic and wound-care products, wearable components, and patient-handling systems. Advanced Components supplies engineered foam, film, plastic, adhesive, and fabric parts for aerospace, defense, automotive, and industrial customers.
Combines materials conversion, precision molding and welding, cleanroom production, prototype development, and commercial-scale assembly across the United States, Ireland, Singapore, Mexico, Costa Rica, and the Dominican Republic. Customer-specific engineering and access to specialized materials support long production programs for device makers. Most sales come from regulated medical markets, and the two largest customers together account for nearly half of revenue.
Company facts
Categories
Key statistics
Year to date +34.4% · Average volume (30d) 172.6K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | $2.31 | $2.69 | +16.5% | $159.4M | $174.0M | +9.1% | +25.16% |
| May 4, 2026Q1 FY26 | $2.18 | $2.48 | +13.8% | $154.8M | $154.2M | −0.4% | +10.32% |
| Feb 24, 2026Q4 FY25 | $2.26 | $2.44 | +8.0% | $149.1M | $148.9M | −0.1% | −0.17% |
| Nov 3, 2025Q3 FY25 | $2.22 | $2.39 | +7.7% | $149.1M | $154.6M | +3.7% | +12.05% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $148.1M | $151.2M | $154.6M | $148.9M | $154.2M | $174.0M | |
| Gross profit | $42.2M | $43.5M | $42.7M | $42.0M | $44.4M | $50.9M | |
| Operating income | $23.1M | $24.3M | $23.4M | $21.5M | $23.3M | $28.1M | |
| Net income | $17.2M | $17.2M | $16.4M | $17.6M | $17.5M | $20.9M | |
| Diluted EPS | $2.21 | $2.21 | $2.11 | $2.24 | $2.24 | $2.68 | |
| Gross margin | 28.5% | 28.8% | 27.7% | 28.2% | 28.8% | 29.3% | |
| Operating margin | 15.6% | 16.1% | 15.1% | 14.4% | 15.1% | 16.2% |
Fiscal years (4-quarter sums)FY21 $206.3M · FY22 $353.8M · FY23 $400.1M · FY24 $504.4M · FY25 $602.8M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $9.0M · Total debt $136.3M · Total assets $681.9M · Shareholders' equity $462.4M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 7.74M · Float 7.43M · 96.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 1.14M | 14.75% | 13F | Aug 7, 2026 |
| Congress Asset Management Co /MA | 687.4K | 8.89% | 13F | Jul 7, 2026 |
| Wasatch Advisors LP | 683.3K | 8.83% | 13F | Jul 10, 2026 |
| Neuberger Berman Group LLC | 537.0K | 6.90% | 13G | Jul 7, 2026 |
| Vanguard Capital Management | 387.8K | 5.01% | 13G | Jul 31, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Marc D. Kozin | director | −7,000 | $304.50 |
| Aug 18, 2026 | Symeria Hudson | director | −298 | $319.11 |
| Aug 14, 2026 | Symeria Hudson | director | −1,926 | $324.58 |
| Aug 13, 2026 | Cynthia L. Feldmann | director | −1,000 | $324.26 |
| Aug 10, 2026 | R. Jeffrey Bailly | director, officer: Executive Chairman | −13,011 | $316.13 |
Peers
- Integer
Medtech CDMO peer across outsourced device components and assemblies
- Jabil
Scaled healthcare manufacturing alternative for regulated OEM programs
- Flex
End-to-end manufacturing rival in medical devices and drug delivery
- Nordson
Medical components and interventional systems overlap with UFP MedTech
- AptarGroup
Pharma packaging and drug-delivery component peer
- Amcor
Large healthcare packaging rival after Berry merger
- Avient
Specialty polymer materials peer for medical-device inputs
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| UFP Technologies | $300.05 | −0.05% | $2.32B | 32.4 | 29.7 | 3.7 | +15.1% |
| Integer | $125.33 | +0.01% | $4.26B | 34.2 | 18.8 | 2.3 | −2.6% |
| Jabil | $303.90 | +0.82% | $31.59B | 37.6 | 19.1 | 0.9 | +11.8% |
| Flex | $110.65 | +0.15% | $40.82B | 42.7 | 21.2 | 1.4 | +20.6% |
| Nordson | $324.59 | +0.01% | $18.09B | 32.8 | 25.8 | 6.1 | +10.3% |
| AptarGroup | $132.99 | −0.02% | $8.49B | 24.0 | 22.4 | 2.2 | +6.3% |
| Amcor | $46.80 | +0.28% | $21.58B | 19.6 | 10.7 | 0.9 | +25.9% |
| Avient | $44.67 | −0.02% | $4.10B | 24.1 | 13.7 | 1.2 | +5.8% |
| Median | 32.8 | 19.1 | 1.4 | +10.3% |